Total amount: € 0,00
Errichetti E., Piccirillo A., Ricciuti F., Ricciuti F.
Dipartimento di Dermatologia, Ospedale San Carlo, Potenza, Italia
Pityriasis rosea (PR) is an acute, self-limited, benign, eruptive dermatosis which generally resolves spontaneously within eight weeks. Some authors have emphasized an hypothetical association between PR and two TNF-alpha inhibitors: adalimumab and etanercept. To date, there have appeared in the literature only a double report describing PR during administration of etanercept and a single report of PR related to the use of adalimumab. Here we report the third case of PR likely associated to etanercept administration, which further supports the hypothetical implication of this TNF-alpha inhibitor in the onset of the disease. Finally, we will analyze the general management of PR arising during etanercept therapy.